Anne Hudson Blaes, MD, of the University of Minnesota, discusses the association between aromatase inhibitors, endothelial function, and early heart disease (Abstract S5-07).
Mothaffar Rimawi, MD, of the Smith Breast Center at Baylor College of Medicine, discusses phase II findings from a study evaluating pathologic complete response in patients with HR-positive, HER2-positive disease treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab with or without estrogen deprivation (Abstract S3-06).
Lisa A. Carey, MD, of the University of North Carolina, and Ingrid A. Mayer, MD, of the Vanderbilt-Ingram Cancer Center, discuss the current studies on neoadjuvant systemic treatment in the triple-negative disease setting.
Jennifer A. Ligibel, MD, of Harvard Medical School, discusses the impact of preoperative exercise on breast cancer gene expression (Abstract S5-05).
Jennifer K. Litton, MD, of MD Anderson Cancer Center, and Ann H. Partridge, MD, of the Dana-Farber Cancer Institute, discuss a range of issues for young women with breast cancer, including epidemiologic and biologic differences in younger patients, fertility issues, and pregnancy-associated breast cancer (Poster Discussion 6).
Lisa A. Carey, MD, of the University of North Carolina, discusses a session she moderated on key data presented at SABCS, and gives her expert views on putting the research data into clinical practice.
